BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

The introduction of ORLADEYO has been a runaway success, and this is likely to continue with new payors and subscribers getting on board and international sales just around the corner. With two pivotal trials for BCX9930 in preparation after a very successful P1 trial, the company has another potential blockbuster that can be useful in multiple diseases.

BioCryst Provides Tremendous Option Value

Adaptimmune Therapeutics

Affimed

Aurinia Pharmaceuticals

Axsome Therapeutics

BridgeBio Pharma Inc

Beam Therapeutics

Amicus Therapeutics

SPDR S&P Biotech ETF

These eight stocks could rebound nicely over the next year and beyond.

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

BioCryst's ORLADEYO has made a great start in the market. BCX9930 has started a set of pivotal trials in PNH.

BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway

BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.

BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930

Bionano Genomics

NRX Pharmaceuticals

Bionano Genomics, BioCryst Pharmaceuticals, and NRx Pharmaceuticals all have the potential to make their early shareholders rich.

3 Incredibly Cheap Growth Stocks That Could Make You a Millionaire

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

Royalty Pharma

Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals Inc (NASDAQ: BCRX). The largest buyer of pharmaceutical royalties globally, Royalty Pharma has purchased royalties for $150 million upfront on combined annual net sales of BCX9930 and another earlier stage Factor D inhibitor.

BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo

—Provides funding for BCX9930/oral Factor D program across multiple indications—

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets

Amazon

Chipotle

Crocs

Ross Stores

Shopify

Block

Here are seven top growth stocks investors may want to consider when looking at options in this hyper-growth market right now. The post 7 Top Growth Stocks to Buy as We Step Into November appeared first on InvestorPlace.

7 Top Growth Stocks to Buy as We Step Into November

Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic therapies Data from APeX-S showed patients had more than 80 percent attack free months after switching to ORLADEYO from injectable prophylactic therapies

BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript

The biotech's third quarter was a good one, once you look past the top-line numbers.

Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today

BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021.

BioCryst to Report Third Quarter 2021 Financial Results on November 3

Align Technology

Match Group

Upstart Holdings

These growth stocks could become multi-baggers in the future. Investors should consider them as they start to move at an aggressive pace.

7 Best Growth Stocks to Buy and Hold for the Next 10 Years

Chemocentryx

These two small drugmakers are poised for a long-winded growth spurt.

2 Super-Charged Growth Stocks to Buy Now

CRISPR Therapeutics

Vertex Pharmaceuticals

A stock market that soured on biotech stocks in general is presenting some bargain opportunities.

3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET.

BioCryst to Present at 2021 Cantor Virtual Healthcare Conference

The U.K.'s National Institute for Health and Care Excellence (NICE) has recommended BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Orladeyo (berotralstat) for hereditary angioedema (HAE). The recommendation covers eligible patients 12 years and older if they have at least two attacks per month.

NICE Recommends BioCryst's Hereditary Angioedema Med

RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's (UK) National Institute for Health and Care Excellence (NICE) has recommended ORLADEYO® (berotralstat) for preventing recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older if they have at least two attacks per month. With this recommendation, HAE patients in England, Wales and Northern Ireland will have access to the first oral, once-daily therapy for routine prevention of recurrent HAE attacks.

NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK

For the three months ended June 30, 2021, total revenues were $50.0 million compared to $2.9 million in the second quarter of 2020.

What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant

The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) Rapivab (peramivir injection) The govt will pay approximately $7 million for the Antiviral influenza therapy. The Rapivab purchase will supply the Strategic National Stockpile.

US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst's antiviral influenza therapy, RAPIVAB® (peramivir injection), for approximately $7 million.

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile

RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed former director of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), and former acting surgeon general, Steven Galson, M.D., MPH to its board of directors.

News for BioCryst Pharmaceuticals Stock (BCRX)